A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors

被引：0
|
作者：
Hope E. Uronis
Jingquan Jia
Johanna C. Bendell
Leigh Howard
Neal A. Ready
Paula H. Lee
Mark D. Starr
Andrew Dellinger
Herbert Pang
Andrew B. Nixon
Herbert I. Hurwitz
机构：
[1] Duke University Medical Center,Duke Cancer Institute
[2] Sarah Cannon Research Institute,Department of Biostatistics and Bioinformatics
[3] Duke University Medical Center,Brody School of Medicine
[4] East Carolina University,Department of Mathematics and Statistics
[5] Elon University,School of Public Health
[6] Li Ka Shing Faculty of Medicine,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2015年 / 75卷
关键词：
Intetumumab; Bevacizumab; Angiogenesis; Phase I;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：343 / 352
页数：9
相关论文
共 50 条
  • [1] A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors
    Uronis, Hope E.
    Jia, Jingquan
    Bendell, Johanna C.
    Howard, Leigh
    Ready, Neal A.
    Lee, Paula H.
    Starr, Mark D.
    Dellinger, Andrew
    Pang, Herbert
    Nixon, Andrew B.
    Hurwitz, Herbert I.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (02) : 343 - 352
  • [2] A phase I study of bevacizumab in combination with sunitinib in advanced solid tumors
    Cooney, M. M.
    Garcia, J.
    Brell, J.
    Dreicer, R.
    Beatty, K.
    Mekhail, T.
    Bukowski, R.
    Zwiebel, J.
    Remick, S. C.
    Rini, B. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] Phase I study of dasatinib in combination with bevacizumab in advanced solid tumors
    Kim, G.
    Annunziata, C. M.
    Sarosy, G. A.
    Minasian, L. M.
    Prindiville, S. A.
    Zujewski, J.
    Otten, L.
    Squires, J.
    Houston, N. D.
    Kohn, E. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] Phase I study of paclitaxel in combination with sorafenib and bevacizumab in patients with locally advanced or metastatic solid tumors
    Schultheis, B.
    Neumann, H.
    Roy, R.
    Kummer, G.
    Strumberg, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors
    Emiliano Calvo
    Cristiana Sessa
    Guilherme Harada
    Maria de Miguel
    Carmen Kahatt
    Xarles Erik Luepke-Estefan
    Mariano Siguero
    Carlos Fernandez-Teruel
    Martin Cullell-Young
    Anastasios Stathis
    Alexander Drilon
    Investigational New Drugs, 2022, 40 : 1263 - 1273
  • [6] Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors
    Calvo, Emiliano
    Sessa, Cristiana
    Harada, Guilherme
    de Miguel, Maria
    Kahatt, Carmen
    Luepke-Estefan, Xarles Erik
    Siguero, Mariano
    Fernandez-Teruel, Carlos
    Cullell-Young, Martin
    Stathis, Anastasios
    Drilon, Alexander
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (06) : 1263 - 1273
  • [7] Phase I study with paclitaxel in combination with sorafenib and bevacizumab in patients with locally advanced or metastatic solid tumors
    Schultheis, B.
    Neumann, H.
    Roy, R.
    Heuer, V
    Kummer, G.
    Strumberg, D.
    ONKOLOGIE, 2011, 34 : 110 - 110
  • [8] Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors
    Lin, Chia-Chi
    Calvo, Emiliano
    Papadopoulos, Kyriakos P.
    Patnaik, Amita
    Sarantopoulos, John
    Mita, Alain C.
    Preston, Glenn G.
    Mita, Monica M.
    Rodon, Jordi
    Mays, Theresa
    Yeh, I-Tien
    O'Rourke, Pat
    Takimoto, Chris H.
    Dancey, Janet E.
    Chen, Helen
    Tolcher, Anthony W.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (06) : 1065 - 1071
  • [9] Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors
    Chia-Chi Lin
    Emiliano Calvo
    Kyriakos P. Papadopoulos
    Amita Patnaik
    John Sarantopoulos
    Alain C. Mita
    Glenn G. Preston
    Monica M. Mita
    Jordi Rodon
    Theresa Mays
    I-Tien Yeh
    Pat O’Rourke
    Chris H. Takimoto
    Janet E. Dancey
    Helen Chen
    Anthony W. Tolcher
    Cancer Chemotherapy and Pharmacology, 2009, 63 : 1065 - 1071
  • [10] Preliminary results of a phase I study of bevacizumab (BV) in combination with everolimus (E) in patients with advanced solid tumors
    Bendell, J.
    Lager, J.
    Zafar, Y.
    Yu, D.
    George, D.
    Nixon, A.
    Petros, W.
    Arrowood, C.
    Beci, R.
    Hurwitz, H.
    ANNALS OF ONCOLOGY, 2006, 17 : 67 - 67
12345